Immune DIREcted and Cancer-selective immunoTherapy

Informazioni relative al progetto

I-DireCT

ID dell’accordo di sovvenzione: 813871

DOI

10.3030/813871

Progetto chiuso

Data della firma CE 21 Agosto 2018

Data di avvio 1 Gennaio 2019

Data di completamento 30 Settembre 2023

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale

€ 2 532 975,22

Contributo UE

€ 2 532 975,22

Coordinato da

ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (11)

Frontiers in Immunology EBook
List of PhDs theses
Presentations at Antibody engineering workshops 2

Special IDireCT sessions at international conferences workshops

Presentations at Antibody engineering workshops

Special IDireCT sessions at international conferences workshops

Characterization of new tumour-selective TNFR family-targeted drugs

Characterization of new tumourselective TNFR familytargeted drugs

List of publications I-DireCT

List of publications of all IDireCT members

Update 4 online knowledge bases
Update 2 online knowledge bases
Update 1 online knowledge bases
Identification and pre-clinical validation of tumour-targeted checkpoint drugs

Identification and preclinical validation of tumourtargeted checkpoint drugs

Update 3 online knowledge bases

Other (3)

Report on kick-off meeting
Press event
I-DireCT summer school

Websites, patent fillings, videos etc. (1)

Website

I-DireCT public website

Pubblicazioni

Peer reviewed articles (20)

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Autori: Ewa Cendrowicz; Lisa Jacob; Shirley Greenwald; Ami Tamir; Iris Pecker; Rinat Tabakman; Lucy Ghantous; Liat Tamir; Roy Kahn; Jasmine Avichzer; Alexandra Aronin; Shira Amsili; Elina Zorde-Khvalevsky; Yosi Gozlan; Martijn Vlaming; Gerwin Huls; Tom van Meerten; Michal Elhalel Dranitzki; Adam Foley-Comer; Yaron Pereg; Amnon Peled; Ayelet Chajut; Edwin Bremer
Pubblicato in: VOLUME=41;ISSN=0392-9078;TITLE=Journal of experimental & clinical cancer research, Numero 5, 2022, ISSN 1756-9966
Editore: BioMed Central Ltd
DOI: 10.1186/s13046-022-02256-x

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Autori: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Harm Jan Lourens, Nienke van Rooij, Gerwin Huls, Tom van Meerten, Marco de Bruyn, Edwin Bremer
Pubblicato in: Scientific Reports, 2021, ISSN 2045-2322
Editore: Nature Publishing Group
DOI: 10.1038/s41598-021-00007-0

Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily

Autori: Kirstin Kucka, Harald Wajant
Pubblicato in: Frontiers in Cell and Developmental Biology, Numero 8, 2021, ISSN 2296-634X
Editore: Frontiers Media S.A.
DOI: 10.3389/fcell.2020.615141

Whispering Gallery Modes-based biosensors for real-time monitoring and binding characterization of antibody-based cancer immunotherapeutics

Autori: Jimena Álvarez Freile; Ghizlane Choukrani; Kerstin Zimmermann; Edwin Bremer; Lars Dähne
Pubblicato in: Sensors and actuators b-Chemical, 346:130512. Elsevier Science, Numero 4, 2021, ISSN 0925-4005
Editore: Elsevier BV
DOI: 10.1016/j.snb.2021.130512

Development of vaterite particles for therapeutic protein drug delivery and pH-sensitive release mimicking the tumor microenvironment.

Autori: Ghizlane Choukrani, Jimena Álvarez Freile, Wei Wan, Gabriella Egri, Natasha Ustyanovska Avtenyuk (ESR2, UMCG/SURF), Valerie Wiersma, Edwin Bremer, Lars Dähne
Pubblicato in: Particle, 2021, ISSN 2571-712X
Editore: MDPI AG
DOI: 10.1002/ppsc.202100012

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

Autori: Vinicio Melo, Edwin Bremer, John D. Martin
Pubblicato in: Frontiers in immunology, 2022, ISSN 1664-3224
Editore: Frontiers Media S.A.
DOI: 10.3389/fcell.2022.908389

CD24 is a potential immunotherapeutic target for Mantle Cell Lymphoma

Autori: Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, and Edwin Bremer
Pubblicato in: Biomedicines, 2022, ISSN 2227-9059
Editore: MDPI
DOI: 10.3390/biomedicines10051175

Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist

Autori: Kucka, Kirstin; Lang, Isabell; Zhang, Tengyu; Siegmund, Daniela; Medler, Juliane; Wajant, Harald
Pubblicato in: Cell Death and Disease, Vol 12, Iss 4, Pp 1-9 (2021), Numero 6, 2021, ISSN 2041-4889
Editore: Nature Publishing Group
DOI: 10.1038/s41419-021-03633-8

The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

Autori: Vrouyr Bilemjian; Martijn R. Vlaming; Jimena Álvarez Freile; Gerwin Huls; Marco De Bruyn; Edwin Bremer
Pubblicato in: Cancer (Basel), Numero 9, 2023, ISSN 2072-6694
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers14133164

CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism

Autori: Juliane Medler, Kirstin Kucka, Vinicio Melo, Tengyu Zhang, Stefan von Rotenhan, Jakob Ulrich, Edwin Bremer, Michael Hudecek, Andreas Beilhack, and Harald Wajant
Pubblicato in: Theranostics, 2022, ISSN 1838-7640
Editore: Ivyspring International Publisher
DOI: 10.7150/thno.66119

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism.

Autori: Ahmed Aido; Olena Zaitseva; Harald Wajant; Matej Buzgo; Aiva Simaite
Pubblicato in: Pharmaceutics, Numero 6, 2021, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13071072

Galectin-9 has non-apoptotic cytotoxic activity towards Acute Myeloid Leukemia independent of cytarabine resistance.

Autori: Ghizlane Choukrani, Nienke Visser, Natasha Ustyanovska Avtenyuk, Mirjam Olthuis, Glenn Marsman, Emanuele Ammatuna, Harm Jan Lourens, Toshiro Niki, Gerwin Huls, Edwin Bremer and Valerie R. Wiersma.
Pubblicato in: Cell Death Discovery, 2023, ISSN 2058-7716
Editore: Nature Publishing Group
DOI: 10.1038/s41420-023-01515-w

Facing the Challenges of Pharmaceutical Research Using Whispering Gallery Modes-Based Biosensors

Autori: Lars Dähne
Pubblicato in: American Journal of Biomedical Science & Research, Numero 8/2, 2020, Pagina/e 161-162, ISSN 2642-1747
Editore: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001259

Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity

Autori: Natasha Ustyanovska Avtenyuk; Ghizlane Choukrani; Emanuele Ammatuna; Toshiro Niki; Ewa Cendrowicz; Harm Jan Lourens; Gerwin Huls; Valerie R. Wiersma; Edwin Bremer
Pubblicato in: Biomedicines, Vol 10, Iss 66, p 66 (2022), Numero 4, 2021, ISSN 2227-9059
Editore: MDPI
DOI: 10.3390/biomedicines10010066

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.

Autori: Zaitseva O, Hoffmann A, Löst M, Anany MA, Zhang T, Kucka K, Wiegering A, Otto C, Wajant H.
Pubblicato in: Frontiers in immunology, 2023, ISSN 1664-3224
Editore: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1194610

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Autori: Natasha Ustyanovska Avtenyuk, Nienke Visser, Edwin Bremer, Valerie R. Wiersma
Pubblicato in: International Journal of Molecular Sciences, Numero 21/21, 2020, Pagina/e 7820, ISSN 1422-0067
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms21217820

Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival

Autori: Martijn Vlaming, Vrouyr Bilemjian, Jimena Álvarez Freile, Vinicio Melo, Annechien Plat, Gerwin Huls, Hans W. Nijman, Marco de Bruyn, Edwin Bremer
Pubblicato in: Front. Immunol., 2022, ISSN 1664-3224
Editore: Frontiers Media S.A
DOI: 10.3389/fimmu.2022.1031746

Using Nanomedicine to Drive Advances in Cancer Immunotherapy: A Mini Review.

Autori: Choukrani G, Freile JA, Bremer E, Daehne L
Pubblicato in: American Journal of Biomedical Science & Research, 2020, ISSN 2642-1747
Editore: Biomedgrid
DOI: 10.34297/ajbsr.2020.08.001248

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Autori: Vinicio Melo, Levi Collin Nelemans, Martijn Vlaming, Harm Jan Lourens, Valerie R. Wiersma, Vrouyr Bilemjian, Gerwin Huls, Marco de Bruyn, and Edwin Bremer
Pubblicato in: Frontiers in immunology, 2023, ISSN 1664-3224
Editore: Frontiers Media S.A.
DOI: 10.3389/fimmu.2023.1191866

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Autori: Jimena Álvarez Freile; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer
Pubblicato in: Crossref, Numero 2, 2023, ISSN 1664-3224
Editore: Frontiers Media S.A
DOI: 10.3389/fimmu.2023.1233113

Thesis and dissertations (1)

Advancing Cancer Immunotherapy with Nanomedicine

Autori: Ghizlane Choukrani
Pubblicato in: 2023
Editore: University of Groningen
DOI: 10.33612/diss.660794643